Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728895 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02728895 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 24 participants.
The verdict
NCT02728895, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell transplantation \[allo-HSCT\]).
Interventions
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728895
The ClinicalTrials.gov registry entry for NCT02728895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vedolizumab is the first listed.
NCT02728895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728895 about?
NCT02728895 is a clinical study titled "Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT". The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell transplantation \[allo-HS...
What is the current status of trial NCT02728895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-06-15. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02728895?
The interventions under investigation include: Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT02728895?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.